{"id":910476,"date":"2025-11-16T09:36:06","date_gmt":"2025-11-16T14:36:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/"},"modified":"2025-11-16T09:36:06","modified_gmt":"2025-11-16T14:36:06","slug":"shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/","title":{"rendered":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately"},"content":{"rendered":"<h2>\nLead Plaintiff Deadline is January 9, 2026<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  16, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-2LfcxwisWY8hS-p3npwNfbobilRowvQmJFGXRjM52WdPn9_nihLEK2sYGePAoodd-rbMv8GvTzJbf5rgbdj3Q6gIlG0V7NKhMq6VQyQJFpdtsS9yk4IXx6rOJHqjIYsjPCqzgAGYoPBSvIWW9DVeMszxZd-VPqppKjyfTEYv0zqbnkwH1VKzGq6izVfgDY7\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a> reminds purchasers or acquirers of <strong>Telix Pharmaceuticals Ltd. (NASDAQ: TLX)<\/strong><strong>(\u201cTelix\u201d) <\/strong>American Depositary Shares (\u201cADS\u201d) between <strong>February 21, 2025 and August 28, 2025<\/strong> (the \u201cClass Period\u201d) have until <strong>January 9, 2026 <\/strong> to seek appointment as <strong>lead plaintiff.<\/strong><\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J4V2aC7I9g4y0BNbp0p56-20zZtHD5prsepsRZ6GFEYCyl_0yGkSMpG18VvjCEODxZQay8f1g_Kw9FMoF188EPLWT27y6fiMZgbbzHtAhlemWEsLdBDjsYp3ohgdZjK0S_Yoxzvd1z8hkw3Iiez1btrSDa7urA4pOLUvfgVpGUgzZNMLuHApXCe6ZOY8_k2Jgtc1bVVhnacnDiNuAnsJBA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Allegations:<\/strong>\n      <\/p>\n<p>The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives:<\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Overstated progress<\/strong> on the company\u2019s prostate cancer therapeutic candidates.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Overstated the quality<\/strong> of its supply chain and partner operations.<\/li>\n<\/ol>\n<p>\n        <strong>Key Events:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">On February 20, 2025, after market close, Telix held its earnings call for the 2024 fiscal year (the \u201c2024 Call\u201d). In the call, defendants represented that they were <em>\u201cmaking great progress across our therapeutic pipeline, notably in the late-stage assets being brain, kidney and, of course, our prostate cancer program which is now in Phase 3. And we have had some really exciting developments across the next generation pipeline including delivery of a clinical proof-of-concept for our prostate cancer alpha candidate. It has been a year of many acquisitions, and these are supporting the strategic expansion of our pipeline and the build out of our global product delivery or manufacturing infrastructure. So in short, the business looks very different to what it did a year ago and at the end of 2025 it will look very different again as a result of this great progress.\u201d<\/em><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">On July 22, 2025, before the market opened, Telix filed with the United States Securities and Exchange Commission (\u201cSEC\u201d) a current report on Form 6-K reporting that the SEC had issued a subpoena for documents and information relating to the Company\u2019s development of its prostate cancer therapeutic candidates. On July 22, 2025, after market close, Bloomberg published an article entitled \u201cTelix Shares Drop as SEC Probes Disclosures Tied to Prostate Cancer Drug Pipeline.\u201d This article stated that <em>\u201c[Telix] slumped as much as 16%, the most in 21 months, after the Australian developer of radioactive drugs said it received a subpoena from the [SEC] seeking information about disclosures related to its prostate cancer therapeutic candidates.\u201d<\/em> On this news, Telix ADSs fell $1.70 per ADS, or 10.4%, to close at $14.58 on July 23, 2025. The next day, Telix ADSs fell a further $0.69 per ADS, or 4.7%, to close at $13.89 on July 24, 2025.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">On August 28, 2025, Telix posted an announcement on its website that the FDA had issued a Complete Response Letter for its renal cancer drug candidate requesting additional data. On this news, the price of Telix ADSs fell $1.95 per ADS, or 16.1%, to close at $10.15 on August 28, 2025. The next day, Telix ADSs fell a further $0.60 per ADS, or 5.9%, to close at $9.55 on August 29, 2025.<\/li>\n<\/ul>\n<p align=\"center\">\n        <strong>Why\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-2LfcxwisWY8hS-p3npwNfbobilRowvQmJFGXRjM52WdPn9_nihLEK2sYGePAoodWfOrz7Hec8daqHEeyEcBCMsodn3B0qvjuqyvhw_uyVC-2FmgneCIAszb5m5Rd_dyj3U9w_R-S-OBP3n2tJ0dIzyt8mzFdTZdUdc_Kl7sONmfKr5zyAd07wxvsgvlDNO9\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Wolf Haldenstein Adler Freeman &amp; Herz LLP?<\/strong><br \/>\n        <\/a>:<\/p>\n<p align=\"justify\">This illustrious <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FvbpqwgDnASS_nTTJMKbnbgaeDYhkFJaVkZNS457fecXpZwzWR85QMqjc2P01eYBDdiffeV7T2oBJS_BeX6EO-HokX6jnmQgUPIl3741J3jZb6766O8KHvvI-2t3kubE\" rel=\"nofollow\" target=\"_blank\">firm<\/a>, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TrO8_JpljrMXfp0wyiWfjWhM_mAAm79_KQyY-9vTxinfB_XWCYaak-BNLgBKj6ethwim7gE7DpZQ6RA3Q3w1ap7Eg7I0VrnWej8elZg4eh763jIA0DR72RnbHUp-qqlQ15_jb-HKtmOP60V1HiiLBw==\" rel=\"nofollow\" target=\"_blank\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p align=\"justify\">We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-2LfcxwisWY8hS-p3npwNfbobilRowvQmJFGXRjM52WdPn9_nihLEK2sYGePAoodWPPororyIluRikJkZJAyUyMynCx6X_CH3rUYiYhouqvzMP5p0fBt47XK7NGMA59unKYCmV8syiCRdzFG87bVvpIaIXrvOWkFKXYtFcsuD62qgNVtK-u2Y8RBXrgCRcRL\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Phone:<\/strong>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Email:\u00a0<\/strong><br \/>\n          <a href=\"mailto:classmember@whafh.com\" rel=\"nofollow\" target=\"_blank\">classmember@whafh.com<\/a>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Contact Person:<\/strong>\u00a0<a href=\"mailto:gstone@whafh.com\" rel=\"nofollow\" target=\"_blank\">Gregory Stone, Director of Case and Financial Analysis<\/a><\/li>\n<\/ul>\n<p>\n        <strong>Firm Website:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4KikTT3sw__RD87Qwapso9wVsSB6BHdjLZSWjlek0kGIZ-0K4c6FflOH9T_wGn1UJ9qUKQR9gmdqlNJRx2AzaMU7GYqUuEUii7FhR8MF_g909J9dB4tWkWzZWsKGDee-hmfnJHCJrn8efChx9bJKdYUb9sWnIEENMM20v1NU23two5JwGhOe7UTbjP8fw-A8\" rel=\"nofollow\" target=\"_blank\">\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>\n      <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTNmNGU4ZjgtNTBlZi00NmUxLTllNzUtMGFhN2MxYTdhODE1LTEwMjkyNDItMjAyNS0xMS0xNi1lbg==\/tiny\/Wolf-Haldenstein-Adler-Freeman.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lead Plaintiff Deadline is January 9, 2026 NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)(\u201cTelix\u201d) American Depositary Shares (\u201cADS\u201d) between February 21, 2025 and August 28, 2025 (the \u201cClass Period\u201d) have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company\u2019s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, 2025, after market close, Telix held its earnings call &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lead Plaintiff Deadline is January 9, 2026 NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)(\u201cTelix\u201d) American Depositary Shares (\u201cADS\u201d) between February 21, 2025 and August 28, 2025 (the \u201cClass Period\u201d) have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company\u2019s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, 2025, after market close, Telix held its earnings call &hellip; Continue reading &quot;Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-16T14:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\",\"datePublished\":\"2025-11-16T14:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/\"},\"wordCount\":585,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/\",\"name\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\",\"datePublished\":\"2025-11-16T14:36:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","og_description":"Lead Plaintiff Deadline is January 9, 2026 NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)(\u201cTelix\u201d) American Depositary Shares (\u201cADS\u201d) between February 21, 2025 and August 28, 2025 (the \u201cClass Period\u201d) have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company\u2019s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, 2025, after market close, Telix held its earnings call &hellip; Continue reading \"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-16T14:36:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately","datePublished":"2025-11-16T14:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/"},"wordCount":585,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/","name":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=","datePublished":"2025-11-16T14:36:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjU4OSM3MjY2NTEwIzIwMTc2NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}